SavedAdd your journal

Journals / Uludağ Üniversitesi Tıp Fakültesi Dergisi / 2018 / Cilt: 44 - Sayı: 2

What is Subclinical Hypothyroidism? It should be treated?

Subklinik Hipotiroidi Nedir? Tedavi Edilmeli midir?

Özen ÖZ GÜL
Soner CANDER
Canan ERSOY
Pages
129–134
Publication Date
2018-08-01
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In general, the level of thyroid stimulating hormone 10 mU/L, those on treatment are recommended, which are below the level of treatment to be personalized, consideration of patient age, risk factors are recommended.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Although serum free thyroid hormone levels are normal, high levels of thyroid stimulating hormone is more frequent condition in population and is defined as subclinical hypothyroidism.
📊
Key Findings & Data:In general population 3-8 % is seen.
💡
Conclusion & Impact:In general, the level of thyroid stimulating hormone 10 mU/L, those on treatment are recommended, which are below the level of treatment to be personalized, consideration of patient age, risk factors are recommended.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Subklinik hipotiroidi · tiroid fonksiyon testleri · Subclinical hypothyroidism

Abstract

Although serum free thyroid hormone levels are normal, high levels of thyroid stimulating hormone is more frequent condition in population and is defined as subclinical hypothyroidism. In general population 3-8 % is seen. Prevalance of subclinical hypothyroidism increases with age and is more common in women. Most important consequence of subclinical hypothyroidism is progression to overt hypothyroidism. increased risk of cardiovascular disease and a decreased cognitive functions due to subclinical hypothyroidism remains uncertain. Therefore, the consensus about the benefits of levothyroxine treatment is not available. In general, the level of thyroid stimulating hormone 10 mU/L, those on treatment are recommended, which are below the level of treatment to be personalized, consideration of patient age, risk factors are recommended.

Özet

Bireylerin serum serbest tiroid hormon düzeyleri normal değerlerde iken tiroid uyarıcı hormon düzeyinin yüksek olması toplumda oldukça sık görülen bir durumdur ve bu durum subklinik hipotiroidi olarak tanımlanmaktadır. Subklinik hipotiroidi genel populasyonda %3-8 oranında görülmekte, prevalansı yaşla birlikte artmakta ve kadınlarda daha sık görülmektedir. Subklinik hipotiroidinin en önemli sonucu aşikar hipotiroidiye ilerlemedir. Subklinik hipotiroidi ile kardiyovasküler hastalıklarda artış ve bilişsel fonksiyonlarda azalma arasındaki ilişki kesin olarak gösterilememiştir. Bu nedenle levotiroksin tedavisinin faydaları konusunda da fikir birliği bulunmamaktadır. Genel olarak tiroid uyarıcı hormon düzeyi 10 mU/L’nin üzerinde olanlara tedavi önerilmekte, bu düzeylerin altında olanlarda tedavinin kişiselleştirilmesi, hastaların risk faktörleri ve yaşları göz önünde bulundurularak değerlendirilmeleri önerilmektedir.

🔖

Cite This Article

GÜL, Ö. Ö., CANDER, S., ERSOY, C. (2018). What is Subclinical Hypothyroidism? It should be treated?. Uludağ Üniversitesi Tıp Fakültesi Dergisi, Cilt: 44 - Sayı: 2, 129–134. https://ajindex.com/articles/134875

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Cooper DS. Subclinical hypothyroidism. N Engl J Med. 2001; 345(4): 260-5
  2. Türkiye Endokrinoloji ve Metabolizma Derneği, tiroid hastalıkları tanı ve tedavi klavuzu. Subklinik hipotiroidi
  3. Baskı. Tuna matbacılık, Ankara, 2013, 13-15
  4. Surks MI, Hollowell JG. Age-specific distribution of serum thyrotropin and antithyroid antibodies in the US population: implications for the prevalence of subclinical hypothyroidism. J Clin Endocrinol Metab. 2007; 92(12): 4575
  5. Singer PA, Cooper DS, Levy EG, Ladenson PW, Braverman LE, Daniels G, Greenspan FS, McDougall IR, Nikolai TF. Treatment guidelines for patients with hyperthyroidism and hypothyroidism. Standards of Care Committee, American Thyroid Association. 1995; 273: 808-12
  6. Baskin HJ, Cobin RH, Duick DS, Gharib H, Guttler RB, Kaplan MM, Segal RL. American Association of Clinical Endocrinologists medical guidelines for clinical practice fort he evaluation and treatment of hyperthyroidism and hypothyroidism. Endocr Pract 2002; 8: 457-69
  7. Gharib H, Tuttle RM, Baskin HJ, Fish LH, Singer PA, McDermott MT; American Association of Clinical Endocrinologists/American Thyroid Association/Endocrine Society. Subclinical thyroid dysfunction: a joint statement on management from the American Association of Clinical Endocrinologists, the American Thyroid Association, and the Endocrine Society. Endocr Pract. 2004; 10(6): 497-501
  8. Fatourechi V, Klee GG, Grebe SK, Bahn RS, Brennan MD, Hay ID, McIver B, Morris JC 3rd. Effects of reducing the upper limit of normal TSH values. JAMA. 2003; 290(24): 3195-6
  9. Vanderpump MP1, Tunbridge WM, French JM, Appleton D, Bates D, Clark F, Grimley Evans J, Hasan DM, Rodgers H, Tunbridge F, et al. The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham Survey. Clin Endocrinol (Oxf). 1995; 43(1): 55-68
  10. Hollowell JG1, Staehling NW, Flanders WD, Hannon WH, Gunter EW, Spencer CA, Braverman LE. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab. 2002; 87(2): 489-99
  11. Canaris GJ1, Manowitz NR, Mayor G, Ridgway EC. The Colorado thyroid disease prevalence study. Arch Intern Med. 2000; 160(4): 526-34
  12. Hamburger JI, Meier DA, Szpunar WE. Factitious elevation of thyrotopin in euthyroid patients. N Engl J Med. 1985; 313(4): 267-8
  13. Tunbridge WM, Harsoulis P, Goolden AW. Thyroid function in patients treated with radioa